SG Americas Securities LLC Buys New Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

SG Americas Securities LLC bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 9,843 shares of the specialty pharmaceutical company's stock, valued at approximately $544,000.

Several other institutional investors and hedge funds have also recently modified their holdings of ANIP. JPMorgan Chase & Co. raised its holdings in ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock valued at $33,101,000 after acquiring an additional 340,854 shares in the last quarter. Global Alpha Capital Management Ltd. grew its position in ANI Pharmaceuticals by 1.8% during the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock worth $32,005,000 after purchasing an additional 9,500 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $228,000. Thompson Siegel & Walmsley LLC increased its holdings in shares of ANI Pharmaceuticals by 17.6% in the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company's stock valued at $13,731,000 after purchasing an additional 34,416 shares during the period. Finally, Thrivent Financial for Lutherans raised its position in ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock worth $777,000 after buying an additional 299 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company's stock.

Insider Transactions at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 33,481 shares of the firm's stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the sale, the chief executive officer now owns 370,378 shares of the company's stock, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Stephen P. Carey sold 7,500 shares of the business's stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares of the company's stock, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,381 shares of company stock worth $2,441,556. 12.70% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Stock Up 1.2 %

NASDAQ ANIP traded up $0.68 during trading hours on Tuesday, reaching $58.59. 199,431 shares of the company traded hands, compared to its average volume of 171,347. The stock has a market capitalization of $1.23 billion, a PE ratio of -106.53 and a beta of 0.74. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.81. The company has a 50 day moving average of $56.61 and a two-hundred day moving average of $58.48.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to analysts' expectations of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.05 earnings per share. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analysts Set New Price Targets

ANIP has been the subject of several research reports. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. StockNews.com downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday, January 28th. Leerink Partnrs raised shares of ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Finally, Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an "overweight" rating and a $68.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.